• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Coya deems dementia drug R&D plan 'premature,' switches focus

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 12, 2023 at 10:32: AM
via Coya Therapeutics’ plan to treat frontotemporal dementia (FTD) by boosting the function of regulatory T cells (Tregs) is unraveling. Months after putting FTD at the heart of its IPO pitch, the biotech has decided it would be “premature” to continue to study its low-dose formulation of IL-2 in the indication.

article source
 






Top Bottom
Back
Quote